Pyritinol treatment of SDAT patients: evaluation by psychiatric and neurological examination, psychometric testing and rCBF measurements.

Knezevic S, Mubrin Z, Risberg J, Vucinic G, 
Spilich G, Gubarev N, Wannenmacher W.

Department of Neurology, 
University Hospital Centre, Zagreb, Yugoslavia.
Int Clin Psychopharmacol 1989 Jan;4(1):25-38


A group of 26 patients with the diagnosis of Senile Dementia of Alzheimer type (SDAT) was included by random assignment in a double-blind, cross-over trial of pyritinol versus placebo.  The patients had a mild to moderate degree of dementia.  Psychiatric and neurological examination, psychometric testing, and measurement of the regional cerebral blood flow (rCBF) at rest and during mental activation were used to assess treatment effects.  The results of the study showed that pyritinol was associated with a significant improvement in cognitive performance.  RCBF data showed that treatment with pyritinol normalized the pattern of blood flow increase during activation and improved the score on the test used for activation.

HOME               to order

1.     pyritinol  and coma
2.     pyritinol  and head injury
3.     pyritinol  and rheumatoid arthritis
4.     pyritinol  and memory
5.     pyritinol  as a free radical scavenger
6.     pyritinol  and dementia
7.     pyritinol  and dementia
8.     pyritinol  and Alzheimer's
9.     pyritinol  stimulation of neutrophils
10.   pyritinol  vs. Hydergine
11.   pyritinol  and phosphatidylserine
12.   pyritinol  and phosphatidylinositol
13.   pyritinol  and dementia
14.   pyritinol  neurochemical studies
15.   pyritinol  mental disorders
16.   pyritinol  learning by Swiss albino mice